Summary of studies showing use of BRAF/MEK inhibitors in well differentiated or anaplastic thyroid cancer
| Trial | Type of cancer | Study phase | Number of patients in final analysis | Regiment | Objective response rate (RECIST 1.1) |
Comments |
|---|---|---|---|---|---|---|
| Falchook et al.10) | WDTC and ATC | Phase I | 13 | Dabrafenib | 38% (5/13) | Six additional patients had partial response not meeting RECIST criteria |
| White et al.11) | WDTC | Phase II | 2 | Dabrafenib plus trametinib | 0% (0/2) | Disease stability was reached for both patients |
| Brose et al.12) | WDTC | Phase II | 51 | Vemurafenib | 31% (16/51) | Compared prior multi-target TKI use vs. no prior TKI use |
| Subbiah et al.14) | ATC | Phase II | 16 | Dabrafenib plus trametinib | 69% (11/16) | |
| Shah et al.13) | WDTC | Phase II | 46 | Dabrafenib alone or in combination with trametinib | 41% (19/46) | Abstract only Compared dabrafenib vs. combination dabrafenib plus trametinib |
ATC: anaplastic thyroid carcinoma, WDTC: well differentiated thyroid carcinoma